Company: HURA
Filing Date: 2025-06-06
Form Type: 425
Source: 0001193125-25-137145
Chunk: 71

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-06-06
Form: 425
Chunk 71
---
|                          |     | Title: President and Chief Executive Officer |

25

| INVESTOR:            |     |        |
| FOR ENTITY:          |     |        |
| Name of Entity Above |     |        |
| By:                  |     |        |
| (Signature)          |     |        |
|                      |     | Name:  |
|                      |     | Title: |
| INVESTOR:            |     |        |
| FOR INDIVIDUAL       |     |        |
| (Signature)          |     |        |
| Name:                |     |        |

| EIN:     |
| Address: |
| Contact: |
| Email:   |

Total Subscription Amount:, which is payable in four equal tranches of 25% at the First, Second, Third and Fourth Closings. Beneficial Ownership Blocker ☐ 4.99% ☐ 9.99% 26

EXHIBIT A

FORM OF WARRANT

27

Exhibit 99.1 TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy Secures $12.5 million of commitments in a private offering Secures an additional $3.0 million through payment of cash exercise price of warrants Funding provides capital for:

| • |     | Initiation of planned Phase 3 accelerated approval trial of IFx-2.0 targeting 40% enrollment by 2- 2025 
 year end                                                                                                |

| • |     | Acquisition of and initiating a Phase 2 trial in NPM1 mutated AML, a novel VISTA inhibiting antibody through 
 closing of Kineta merger                                                                                     |

| • |     | Advancing first-in-class immune modulating bi-specific, and bi-functional Antibody Drug Conjugates (ADC) and 
 Antibody Peptide Conjugates (APCs)                                                                           |

TAMPA, Fla., June 3, 2025 - TuHURA Biosciences, Inc.(NASDAQ:HURA) (“TuHURA” or “Company”), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that it has entered into a definitive securities purchase agreement for the issuance and sale in a private placement of an aggregate of $12.5 million of shares of its common stock